Daily Dose Equities - Wall Street Analysis for Biomedical Research

Oncothyreon (ONTY): Files IND for ONT-10 - Vaccine for Ovarian Cancer: Can you say PrimaBioMed ?

Tuesday, December 20, 2011 at 8:15AM
DDE Editor in Oncology, oncothyreon, onty, prima biomed, prr

News on the tape today that Oncothyreon (ONTY) has filed an investigational new drug (IND) application for ONT-10. ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the FDA's review of the IND, Oncothyreon expects to initiate a Phase 1 trial of ONT-10. We recently wrote on this and discussed its implications for PrimaBioMed. Please see that note here.

Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).

See website for complete article licensing information.